Table 2.
Multivariate analysis of effects of select prognostic variables and randomized treatment on overall survival and relapse-free survival on study
| Survival | HR | 95% CI | P value |
|---|---|---|---|
| Overall | |||
| Randomized treatment: Oral-AZA vs placebo | 0.732 | 0.5898-0.9074 | .004 |
| NPM1 mutation status at diagnosis: NPM1mut vs NPM1wt | 0.624 | 0.469-0.829 | .001 |
| FLT3 mutation status at diagnosis: FLT3mut (ITD/TKD) vs FLT3wt | 1.444 | 1.023-2.039 | .036 |
| Cytogenetic risk at diagnosis: poor vs intermediate | 1.853 | 1.376-2.495 | <.001 |
| MRD status at screening: MRD+ vs MRD– | 1.716 | 1.380-2.133 | <.001 |
| Relapse-free | |||
| Randomized treatment: Oral-AZA vs placebo | 0.631 | 0.509-0.782 | <.001 |
| NPM1 mutation status at diagnosis: NPM1mut vs NPM1wt | 0.614 | 0.467-0.808 | <.001 |
| FLT3 mutation status at diagnosis: FLT3mut (ITD/TKD) vs FLT3wt | 1.034 | 0.727-1.472 | .851 |
| Cytogenetic risk at diagnosis: poor vs intermediate | 1.753 | 1.294-2.375 | <.001 |
| MRD status at screening: MRD+ vs MRD– | 1.984 | 1.596-2.466 | <.001 |